Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05242731 (ClinicalTrials.gov)	April 29, 2021	23/1/2022	Telemonitoring and Connected Care Applied to Multiple Sclerose	MonSter Study, Telemonitoring and Connected Care Applied to Multiple Sclerose	Multiple Sclerosis	Device: MSmonitor, a self-management/education program with e-health interventions;Device: Video calling program Better-close;Device: Researchmanager program	Isala	NULL	Recruiting	18 Years	N/A	All	208	N/A	Netherlands
2	EUCTR2005-006071-12-IT (EUCTR)	31/08/2005	09/05/2006	Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE	Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE	MULTIPLE SCLEROSIS MedDRA version: 6.1;Level: PT;Classification code 10028245	Trade Name: EPARMEFOLIN 30 CPR 0,1/0,5MG INN or Proposed INN: CALCIO FOLINATO DC.IT INN or Proposed INN: CIANOCOBALAMINA FU DC.IT Trade Name: LEVOFOLENE 4 MG 30 CPR INN or Proposed INN: Calcium levofolinate	AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI	NULL	Not Recruiting			Female: yes Male: yes	276		Italy
3	NCT00913666 (ClinicalTrials.gov)	November 2002	2/6/2009	Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers	A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects	Multiple Sclerosis	Drug: Interferon beta -1a (Avonex)	Biogen Idec	NULL	Completed	18 Years	65 Years	Both	121	Phase 4	NULL